Reduction of interval cancer: in aggregate, the MASAI trial observed a large increase in cancer detection (29% increase in ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial evaluating whether ...
Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across ...
Time to Progression in Metastatic Breast Cancer Patients Treated With Epirubicin Is Not Improved by the Addition of Either Cisplatin or Lonidamine: Final Results of a Phase III Study With a Factorial ...
DANVERS, Mass. – October 24, 2024 – Novel data on the benefits of Impella ® heart pump technology in high-risk percutaneous coronary intervention (PCI) and cardiogenic shock will be presented during ...
Central retinal artery occlusion can result in permanent vision loss. Effective treatment is lacking. We conducted a phase 3, double-blind, double-dummy, randomized, controlled trial involving ...
CLEVELAND, Ohio (Sept 10, 2024) –Menopausal women are at greater risk of insulin resistance as a result of declining estrogen levels. Previous studies evaluating the potential benefits of hormone ...
MADRID, Aug. 31, 2025 /PRNewswire/ --Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously ...
Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ManagerAtlantia Clinical Trials Food clinical trials may not be as familiar to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results